Use of Proteasome Inhibition in the Treatment of Lung Cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference59 articles.
1. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-smallcell lung cancer (NSCLC) stages III and IV: a phase III randomised trial;Grigorescu;Lung Cancer,2002
2. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer;Mazzanti;Lung Cancer,2003
3. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer;Scagliotti;J Clin Oncol,2002
4. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial;Zatloukal;Lung Cancer,2003
5. Carboplatin/gemcitabine combination in advanced NSCLC;Ramalingam;Oncology (Huntingt),2004
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence;Health Science Reports;2023-11
2. Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553);Investigational New Drugs;2017-02-16
3. A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer;Cancer Chemotherapy and Pharmacology;2016-03-19
4. Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells;Mini-Reviews in Medicinal Chemistry;2012-09-01
5. The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer;Journal of Biomedicine and Biotechnology;2011
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3